Trial reportPloS one2026
Erythropoietin, transfusions, and outcomes of retinopathy of prematurity and brain injury in extremely preterm infants: A post hoc analysis of the Preterm Erythropoietin Neuroprotection Trial (PENUT).
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundErythropoietin is perceived as both a neuroprotectant and a biomarker for hypoxic stress.
objectiveTo explore correlations between serum erythropoietin (Epo) concentrations, perinatal risk factors, red blood cell transfusions and recombinant human erythropoietin (rHuEpo) with outcomes including retinopathy of prematurity (ROP) and brain injury on magnetic resonance imaging (MRI) in extremely preterm infants.
methodsThis is a post hoc analysis of data from the Preterm Erythropoietin Neuroprotection Trial of preterm infants born between 24 0/7 and 27 6/7 weeks gestation and randomized to placebo or rHuEpo treatment (N = 941). Serum Epo concentrations were collected within 24 hours (baseline) and at 7, 9, and 14 days. MRI was obtained at 36 weeks postmenstrual age (N = 220).
resultsBaseline Epo concentrations negatively correlated with gestational age, delayed cord clamping, and Apgar scores, and positively correlated with intraventricular hemorrhage and risk of death. Neither endogenous Epo at baseline nor trajectories from birth to 14 days were associated with ROP. In the placebo group, Epo at 1 week of life (r = 0.26, p = 0.033) and 2-week area under the curve (r = 0.28, p = 0.019) positively correlated with white matter injury. In the treatment group, Epo at 14 days negatively correlated with white matter injury (r = -0.35, p = 0.004). Grey matter injury negatively correlated with baseline Epo in the placebo group (r = -0.27, p = 0.01) but positively correlated in the treatment group (r = 0.23, p = 0.047). Transfusions were associated with severe ROP (p < 0.0001) and total brain injury on MRI (p = 0.007). Transfusion volumes in the first week of life were associated with a greater risk of severe ROP in males (p = 0.0006).
conclusionsEndogenous Epo concentrations in preterm infants are influenced by perinatal variables and correlate with poor outcomes. The association of Epo with MRI results differed between placebo and rHuEpo treatment groups. Transfusions were associated with increased ROP and brain injury on MRI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.